Use of sirolimus in solid organ transplantation

Drugs

Volumn 67, Issue 3, 2007, Pages 369-391

  Augustine, Joshua J ^a   Bodziak, Kenneth A ^a   Hricik, Donald E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DACLIZUMAB; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHENYTOIN; PLACEBO; PREDNISONE; RAPAMMUNE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG; VERAPAMIL; VORICONAZOLE;

ACNE; ANEMIA; APHTHOUS ULCER; BLOOD VESSEL OCCLUSION; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL CYCLE PROGRESSION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYELID EDEMA; FOLLICULITIS; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOLOGICAL TOLERANCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; LEG EDEMA; LEUKOPENIA; LIP FISSURE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MOUTH ULCER; NAIL DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMONIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; WOUND HEALING IMPAIRMENT;

CHILD; DRUG APPROVAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PROTEIN KINASES; SIROLIMUS;

MAMMALIA;

EID: 33947193386     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767030-00004     Document Type: Review

References (180)

1. Sehgal SN. Immunosuppressive profile of rapamycin. Ann N Y Acad Sci 1993; 696: 1-8
2. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; II: 227
3. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989; 17: 877-81
4. Neuhas P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liver Transpl 2001; 7: 473-84
5. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998; 30: 2200-3
6. Salminen US, Alho H, Taskinen E, et al. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model. Transplant Proc 1998; 30: 2204-5
7. Abraham RT, Wiederrrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol 1996; 14: 483-510
8. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42
9. Schmidbauer G, Hancock W, Wasowska B, et al. Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion. Transplantation 1994; 57: 933-41
10. Li Y, Zheng X, Li X, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998; 66: 1387-8
11. Wells A, Li X, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303-7
12. Li Y, Li X, Zheng X, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-305
13. Kahan BD, Kramer WG. Median effect analysis of efficacy versus effects of immunosuppressants. Clin Pharmacol Ther 2001; 70: 74-81
14. Dumont FJ, Melino MR, Staruch MJ, et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418-24
15. Chen H, Peng J, Luo H, et al. Compromised kidney graft rejection response in vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation 2000; 69: 1555-61
16. Khanna A, Plummer M, Bromberek K, et al. Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy. Med Immunol 2002; 1: 3
17. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405-15
18. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc 1996; 38: 970-3
19. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 Suppl. B: B101-21
20. Zimmerman JJ, Ferron GM, Lim HK, et al. The effect of a high- fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999; 39: 1155-61
21. Kelly PA, Napoli K, Kahan BD. Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. Biopharm Drug Dispos 1999; 20: 249-53
22. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
23. Gallant-Haidner HL, Trepanier DK, Freitag DG, et al. Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit 2000; 22: 31-5
24. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356: 194-202
25. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573-85
26. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005; 44: 769-86
27. Brattstrom C, Sawe J, Tyden G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997; 19: 397-406
28. Kahan BD, Napoli KL. Role of therapeutic drug monitoring of rapamycin. Transplant Proc 1998; 30: 2189-91
29. Yatscoff R, LeGatt D, Kennan R, et al. Blood distribution of rapamycin. Transplantation 1993; 56: 1202-6
30. Streit F, Christians U, Scheibel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 1996; 42: 1417-25
31. Napoli KL, Kahan BD. Sample clean-up and high-performance liquid chromatographic techniques for measurement of whole blood rapamycin concentrations. J Chromatogr B Biomed Appl 1994; 654: 111-20
32. Jones K, Saadat-Lajevardi S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther 2000; 22 Suppl. B: B49-61
33. Bai S, Stepkowski SM, Kahan BD, et al. Metabolic interaction between cyclosporine and sirolimus. Transplantation 2004; 77: 1507-12
34. McAlister VC, Mahalati K, Peltekian KM, et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346-50
35. Kahan BD, Podbielski H, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-6
36. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68: 1526-32
37. MacDonald AS. A worldwide phase III randomised, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-80
38. Podder H, Podbielski J, Hussein I, et al. Sirolimus improves the two-year outcome of renal allografts in African American patients. Transpl Int 2001; 14: 135-42
39. Formica RN, Lorber KM, Friedman AL, et al. Sirolimus-based immunosuppression with reduced dose cyclosporine or tacrolimus after renal transplantation. Transplant Proc 2003; 35 Suppl. 2: 95-8S
40. Kahan BD, Knight R, Schonberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: 25-34S
41. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-7
42. Shapiro R, Scantlebury VP, Jordan ML, et al. A pilot trial of tacrolimus, sirolimus, and steroids in renal transplant recipients. Transplant Proc 2002; 34: 1651-2
43. Hartwig T, Pridohl O, Witzigmann H, et al. Low-dose sirolimus and tacrolimus in kidney transplantation: first results of a single-center experience. Transplant Proc 2001; 33: 3226-8
44. Hricik DE, Anton HAS, Knauss TC, et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 2002; 74: 189-93
45. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet cell transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppression regimen. N Engl J Med 2000; 343: 230-8
46. van Hoof JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal transplant recipients. Transplantation 2003; 75: 1934-9
47. Gonwa T, Mendez R, Yang HC, et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213-20
48. Mendez R, Gonwa T, Tang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303-9
49. Ciancio C, Burke GW, Gaytnor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252-8
50. Meier-Kriesch HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273-80
51. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to Rapamycin immunosuppression in renal transplant recipients. Transplantation 2000; 70: 1244-7
52. Wyzgal J, Paczek L, Senatorski G, et al. Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc 2002; 34: 3185-7
53. Diekmann F, Waiser J, Fritsche L, et al. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin-inhibitor nephrotoxicity. Transplant Proc 2001; 33: 3234-5
54. Egidi MF, Cowan PA, Naseer A, et al. Conversion to sirolimus in solid organ transplantation: a single center experience. Transplant Proc 2003; 35 Suppl. 3: 131-7S
55. Schena FP, Wali RK, Pascoe MD, et al. Efficacy and safety of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients: 12 month results from a large, randomized, open-label, comparative trial [abstract]. J Am Soc Nephrol 2005; 16: 32A
56. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-86
57. Gonwa TA, Hricik DE, Brinker K, et al. Sirolimus Renal Function Study Group: improved renal function in sirolimus treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-7
58. Baboolal K. A phase III prospective randomized study to evaluate concentration controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003; 75: 1404-8
59. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporin A improves one year kidney graft structure and function in sirolimus treated patients. Transplantation 2003; 75: 998-1003
60. Jardine AG. Phase III prospective randomized study to evaluate the safety and efficacy of concentration controlled Rapamune (sirolimus) with cyclosporine dose minimization or elimination in denovo renal allograft recipients at 12 months [abstract]. Am J Transplant 2004; 4 Suppl. 8: S286
61. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308-14
62. Oberauer R, Kreis H, Johnson RW, et al. Rapammune Maintenance Regimen Study Group: long term improvement in renal function with sirolimus after early cyclosporin withdrawal in renal transplant recipients: 2-year results of the Rapammune Maintenance Regimen Study. Transplantation 2003; 76: 364-70
63. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748-56
64. Groth CG, Backman L, Morales JM, et al. Sirolimus (Rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-42
65. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-60
66. Morales JM, Wrammer L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-42
67. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1770-6
68. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-85
69. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77: 1228-35
70. Knechtle SJ, Pirsch J, Fechner J, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30
71. Kirk A, Hale D, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003; 76: 120-9
72. Flechner SM, Friend PJ, Brockman J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free transplant immunosuppression. Am J Transplant 2005; 5: 3009-14
73. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine combination therapy. Transplant Proc 2001; 33: 1270-2
74. Woodle ES, Vincenti F, Lorber MI, et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 2005; 5: 157-66
75. Hricik DE, Knauss TC, Bodziak KA, et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76: 938-42
76. Hricik DE, Knauss TC, Bodziak KA, et al. Suboptimal long-term outcomes after steroid withdrawal in African Americans receiving sirolimus and tacrolimus [abstract]. Am J Transplant 2005; 5 Suppl. 11: S287
77. Kumar AMS, Moritz MJ, Saaed MI, et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5: 1976-85
78. Vincenti F, Stock P. De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc 2003; 35 (3 Suppl.): 183-6S
79. Rogers J, Ashcraft EE, Emovon OE, et al. Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. Transplantation 2004; 78: 619-22
80. Lehmann R, Weber M, Berthold P, et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. Am J Transplant 2004; 4: 1117-23
81. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35 (3 Suppl.): 209-16S
82. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-8
83. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-51
84. Kniepeiss D, Iberer F, Grasser B, et al. Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003; 16: 504-9
85. Fairbanks KD, Eustace JA, Fine D, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079-85
86. Sahin F, Kannangai R, Adegbola O, et al. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-5
87. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-11
88. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc 2004; 36 (2 Suppl.): 5000-33S
89. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiactransplant recipients. N Engl J Med 2003; 349: 847-58
90. Keogh AM, the Sirolimus Cardiac Transplant Trial Group. Sirolimus immunotherapy reduces the rates of cardiac allograft rejection: 6-month results from a phase 2, open-label study [abstract]. Am J Transplant 2002; 2 Suppl. 3: S246
91. Groetzner J, Meiser B, Landehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77: 568-74
92. Meiser B, Reichart B, Adamidis I, et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 2005; 5: 827-31
93. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet 2002; 359: 619-22
94. Ikonen TS, Gummert JF, Serkova N, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13 Suppl. 1: S314-20
95. Eisen H, Kobashigawa J, Starling RC, et al. Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors. Transplant Proc 2005; 37 (4 Suppl.): 4-17S
96. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437-43
97. Grotzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23: 632-8
98. Shitrit D, Rahamimov R, Gidon S, et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int 2005; 67: 1471-5
99. Villanueva J, Boukhamseen A, Bhorade SM. Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus. J Heart Lung Transplant 2005; 24: 421-5
100. Ussetti P, Laporta R, de Pablo A, et al. Rapamycin in lung transplantation: preliminary results. Transplant Proc 2003; 35: 1974-7
101. Venuta F, De Giacomo T, Rendina EA, et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004; 78: 1940-3
102. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant 2005; 9: 520-2
103. Sindhi R, Seward J, Mazariegos G, et al. Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatr Transplant 2005; 9: 391-7
104. Lobach NE, Pollock-Barziv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 2005; 24: 184-9
105. Kahan BD, Napoli KL, Kelly PA, et al. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 2000; 14: 97-109
106. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001; 72: 1244-50
107. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43: 1170-80
108. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-35
109. Blum CB. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2002; 2: 551-9
110. Barshes NR, Goodpastor SE, Goss JA. Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation 2003 Dec 15; 76 (11): 1649-50
111. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-70
112. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-5
113. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3: 562-9
114. Ikonen TS, Gummert JF, Serkova N, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int 2000; 13 Suppl. 1: S314-20
115. Chueh SC, Kahan BD. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 2003; 76: 375-82
116. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67: 1036-42
117. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000; 69: 2085-90
118. Mix TC, Kazmi W, Khan S. Anemia: a continuing problem following kidney transplantation. Am J Transplant 2003; 3: 1426-33
119. Bouscary D, Pene F, Claessens YE. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003; 101: 3436-43
120. Cruz R, Hedden L, Boyer D, et al. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. J Leukoc Biol 2005; 78: 1378-85
121. Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001-6
122. Andoh TF, Lindsley J, Franceschini N, et al. Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311-6
123. Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-71
124. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35 (3 Suppl.): 37-51S
125. Masterson R, Leikis M, Perkovic V, et al. Sirolimus: a single center experience in combination with calcineurin inhibitors. Transplant Proc 2003; 35 (3 Suppl.): 99-104S
126. Andoh TF, Burdmann EA, Fransechini N, et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 1110-7
127. Shihab FS, Bennett WM, Yi H, et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004; 65: 1262-71
128. Augustine JJ, Chang PC, Knauss TC, et al. Improved renal function after conversion from tacrolimus/sirolimus to tacrolimus/mycophenolate mofetil in kidney transplant recipients. Transplantation 2006; 81: 1004-9
129. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-706
130. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-23
131. Smith KD, Wrenshall LE, Nicosia RF, et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037-45
132. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78: 1362-6
133. Saurina A, Campistol JM, Piera C, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant. Epub 2005 Nov 9
134. Dervaux T, Caillard S, Meyer C, et al. Is sirolimus responsible for proteinuria? Transplant Proc 2005; 37: 2828-9
135. Senior PA, Paty BW, Cockfield SM, et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 2005; 5: 2318-23
136. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-75
137. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76: 1729-34
138. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003; 3: 1128-34
139. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-61
140. Rogers CC, Hanaway M, Alloway RR, et al. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. Transplant Proc 2005; 37: 795-7
141. Kandaswamy R, Melancon JK, Dunn T, et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: an interim analysis. Am J Transplant 2005; 5: 1529-36
142. Goel M, Flechner SM, Zhou L, et al. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation. J Urol 2004; 171: 1788-92
143. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804-8
144. Gaben AM, Saucier C, Bedin M, et al. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J Cancer 2004; 108: 200-6
145. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004; 279: 23166-75
146. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002; 16: 771-80
147. Neff GW, Ruiz P, Madariaga JR, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004; 38: 1593-6
148. Montalbano M, Neff GW, Yamashiki N, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264-8
149. Wadei H, Gruber SA, El-Amm JM, et al. Sirolimus-induced angioedema. Am J Transplant 2004; 4: 1002-5
150. Mahe E, Morelon E, Lechaton S, et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005; 79: 476-82
151. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 2001; 72: 162-4
152. Aboujaoude W, Milgrom ML, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 2004; 77: 1094-6
153. Romagnoli J, Citterio F, Nanni G, et al. Severe limb lymphedema in sirolimus-treated patients. Transplant Proc 2005; 37: 834-6
154. van Gelder T, ter Meulen CG, Hene R, et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003; 75: 788-91
155. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496-503
156. Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004; 4: 1084-8
157. Tondolo V, Citterio F, Panocchia N, et al. Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 2005; 37: 1915-7
158. Meachem SJ, Ruwanpura SM, Ziolkowski J, et al. Developmentally distinct in vivo effects of FSH on proliferation and apoptosis during testis maturation. J Endocrinol 2005; 186: 429-46
159. Lecureuil C, Tesseraud S, Kara E, et al. Follicle-stimulating hormone activates p70 ribosomal protein S6 kinase by protein kinase A-mediated dephosphorylation of Thr 421/Ser 424 in primary Sertoli cells. Mol Endocrinol 2005; 19: 1812-20
160. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit upregulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 2000; 275: 25572-6
161. Robson M, Cote I, Abbs I, et al. Thrombotic microangiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003; 3: 324-7
162. Barone GW, Gurley BJ, Abul-Ezz SR, et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant patient. Am J Kidney Dis 2003; 42: 202-6
163. Franco A, Hernandez D, Capdevilla L, et al. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 2003; 35: 1764-6
164. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441-7
165. Garrean S, Massad MG, Tshibaka M, et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005; 19: 698-703
166. Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant 2005; 5: 1392-6
167. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004; 77: 1215-20
168. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4
169. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-?1 expression and promotes tumor progression. Transplantation 2003; 76: 597-602
170. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-72
171. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917-26
172. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35
173. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472-80
174. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients; results from five multicenter studies. Clin Transplant 2004; 18: 446-9
175. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-9
176. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-2
177. Sierka D, Kumar MS, Heifets M, et al. Successful minimization of immunosuppression and conversion to sirolimus in kidney transplant recipients with posttransplant lymphoproliferative disease (PTLD) and de novo nonskin malignancies [abstract]. Am J Transplant 2004; 4 Suppl. 8: 523
178. Ozaki KS, Camara NO, Galante NZ, et al. Decreased cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol 2005; 5: 103-6
179. Gruber SA, Garnick J, Morawski K, et al. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. Clin Transplant 2005; 18: 273-8
180. Trotter JF, Wollack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transpl Infect Dis 2003; 5: 174-80